TY - JOUR T1 - Metagenomic sequencing of municipal wastewater provides a near-complete SARS-CoV-2 genome sequence identified as the B.1.1.7 variant of concern from a Canadian municipality concurrent with an outbreak JF - medRxiv DO - 10.1101/2021.03.11.21253409 SP - 2021.03.11.21253409 AU - Chrystal Landgraff AU - Lu Ya Ruth Wang AU - Cody Buchanan AU - Matthew Wells AU - Justin Schonfeld AU - Kyrylo Bessonov AU - Jennifer Ali AU - Erin Robert AU - Celine Nadon Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/17/2021.03.11.21253409.abstract N2 - Laboratory-based wastewater surveillance for SARS-CoV-2, the causative agent of the ongoing COVID-19 pandemic, can be conducted using RT-qPCR-based screening of municipal wastewater samples. Although it provides rapid viral detection and can inform SARS-CoV-2 abundance in wastewater, this approach lacks the resolution required for viral genotyping and does not support tracking of viral genome evolution. The recent emergence of several variants of concern, a result of mutations across the genome including the accrual of important mutations within the viral spike glycoprotein, has highlighted the need for a method capable of detecting the cohort of mutations associated with these and newly emerging genotypes. Here we provide an innovative methodology for the recovery of a near-complete SARS-CoV-2 sequence from a wastewater sample collected from across Canadian municipalities including one that experienced a significant outbreak attributable to the SARS-CoV-2 B.1.1.7 variant of concern. Our results demonstrate that a combined interrogation of genome consensus-level sequences and alternative alleles enables the identification of a SARS-CoV-2 variant of concern and the detection of a new allele within a viral accessory gene that may be representative of a recently evolved B.1.1.7 sublineage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was conducted using funding provided by the Public Health Agency of Canada ( internal funding only)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study did not require ethics approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis manuscript acknowledges the sampling and use of data obtained from the GISIAD database. The Oxford Nanopore sequencing reads generated in this study were deposited into NCBI BioProject PRJNA708265 and BioSample accession SAMN18228019. https://www.gisaid.org/ ER -